ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy

The mismatch repair (MMR) deficiency of cancer cells drives mutagenesis and offers a useful biomarker for immunotherapy. However, many MMR-deficient (MMR-d) tumors do not respond to immunotherapy, highlighting the need for alternative approaches to target MMR-d cancer cells. Here, we show that inhib...

Full description

Saved in:
Bibliographic Details
Published in:Genes & development 2023-10, Vol.37 (19-20), p.929-943
Main Authors: Wang, Mingchao, Ran, Xiaojuan, Leung, Wendy, Kawale, Ajinkya, Saxena, Sneha, Ouyang, Jian, Patel, Parasvi S, Dong, Yuting, Yin, Tao, Shu, Jian, Manguso, Robert T, Lan, Li, Wang, Xiao-Fan, Lawrence, Michael S, Zou, Lee
Format: Article
Language:English
Subjects:
Animals
CD8-Positive T-Lymphocytes
DNA
DNA Mismatch Repair - genetics
Immunotherapy
Mice
Research Papers
Synthetic Lethal Mutations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mismatch repair (MMR) deficiency of cancer cells drives mutagenesis and offers a useful biomarker for immunotherapy. However, many MMR-deficient (MMR-d) tumors do not respond to immunotherapy, highlighting the need for alternative approaches to target MMR-d cancer cells. Here, we show that inhibition of the ATR kinase preferentially kills MMR-d cancer cells. Mechanistically, ATR inhibitor (ATRi) imposes synthetic lethality on MMR-d cells by inducing DNA damage in a replication- and MUS81 nuclease-dependent manner. The DNA damage induced by ATRi is colocalized with both MSH2 and PCNA, suggesting that it arises from DNA structures recognized by MMR proteins during replication. In syngeneic mouse models, ATRi effectively reduces the growth of MMR-d tumors. Interestingly, the antitumor effects of ATRi are partially due to CD8 T cells. In MMR-d cells, ATRi stimulates the accumulation of nascent DNA fragments in the cytoplasm, activating the cGAS-mediated interferon response. The combination of ATRi and anti-PD-1 antibody reduces the growth of MMR-d tumors more efficiently than ATRi or anti-PD-1 alone, showing the ability of ATRi to augment the immunotherapy of MMR-d tumors. Thus, ATRi selectively targets MMR-d tumor cells by inducing synthetic lethality and enhancing antitumor immunity, providing a promising strategy to complement and augment MMR deficiency-guided immunotherapy.
ISSN:0890-9369
1549-5477
DOI:10.1101/gad.351084.123